Patient outcomes after therapy with 177 Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.
- Resource Type
- Article
- Authors
- Losee, Meryam; Vaz, Nuno; Ritzer, Jolivette; Wolanski, Andrew; Bhimaniya, Sudhir; Choudhury, Atish Dipankar; Hyun, Hyewon; Kelly, Emma; Kilbridge, Kerry L.; Morgans, Alicia K.; Pomerantz, Mark; Robertson, Matthew; Sakellis, Christopher; Shah, Hina; Sunkara, Rajitha; Taplin, Mary-Ellen; Wei, Xiao X.; Whelpley, Bridget; Ravi, Praful; Jacene, Heather
- Source
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p87-87, 235p
- Subject
- Language
- ISSN
- 0732183X